Story thread · 3 reports / 2 sources
Helus Pharma Presents New Analyses on HLP003 in Major Depressive Disorder at Psych Congress 2026
financialpost.com · 12h · first report
Poster presentations further characterize clinical profile of HLP003 and Phase 3 PARADIGM program evaluating HLP003 as a potential adjunctive treatmentfor major depressive disorder (“MDD”) NEW YORK and TORONTO, Sept. 21, 2026 (GLOBE NEWSWIRE) — Helus Pharma (Nasdaq: HELP) (Cboe CA: HELP) (the “Company” or “Helus Pharma”), a clinical-stage pharmaceutical company committed to helping minds heal […]
The coverage
The conversation · 0
Sign in to join the conversation.
No comments yet — start the thread.